Thornburg Investment Management Inc. trimmed its stake in Gilead Sciences (NASDAQ:GILD) by 5.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,172,470 shares of the biopharmaceutical company’s stock after selling 71,015 shares during the period. Thornburg Investment Management Inc.’s holdings in Gilead Sciences were worth $88,393,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Macquarie Group Ltd. increased its stake in shares of Gilead Sciences by 26.6% in the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock worth $38,836,000 after purchasing an additional 100,741 shares in the last quarter. Parnassus Investments CA increased its stake in shares of Gilead Sciences by 2.5% in the 4th quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock worth $1,372,604,000 after purchasing an additional 464,609 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Gilead Sciences by 5.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 4,959,388 shares of the biopharmaceutical company’s stock worth $401,810,000 after purchasing an additional 252,556 shares in the last quarter. Hyman Charles D increased its stake in Gilead Sciences by 35.9% in the 4th quarter. Hyman Charles D now owns 4,164 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 1,100 shares in the last quarter. Finally, Sterling Capital Management LLC increased its stake in Gilead Sciences by 4.8% in the 3rd quarter. Sterling Capital Management LLC now owns 1,219,771 shares of the biopharmaceutical company’s stock worth $98,826,000 after buying an additional 56,020 shares in the last quarter. Hedge funds and other institutional investors own 78.16% of the company’s stock.
Shares of Gilead Sciences opened at $67.55 on Thursday, MarketBeat reports. The company has a quick ratio of 2.75, a current ratio of 2.84 and a debt-to-equity ratio of 1.32. Gilead Sciences has a 12 month low of $67.01 and a 12 month high of $67.62. The stock has a market capitalization of $87.10 billion, a P/E ratio of 7.89, a price-to-earnings-growth ratio of -5.82 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 EPS for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same period in the previous year, the business posted $2.23 EPS. The firm’s revenue was down 21.8% on a year-over-year basis. sell-side analysts forecast that Gilead Sciences will post 5.75 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Investors of record on Friday, June 15th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.38%. The ex-dividend date of this dividend is Thursday, June 14th. Gilead Sciences’s payout ratio is 26.64%.
A number of equities research analysts have issued reports on GILD shares. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a research note on Wednesday, January 17th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price objective for the company from $88.80 to $76.00 in a report on Tuesday, January 30th. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Finally, Jefferies Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $81.19 to $93.00 in a report on Friday, January 26th. One analyst has rated the stock with a sell rating, ten have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $88.14.
In related news, Director John Francis Cogan sold 5,836 shares of the stock in a transaction dated Friday, May 4th. The shares were sold at an average price of $65.09, for a total value of $379,865.24. Following the completion of the transaction, the director now owns 58,455 shares of the company’s stock, valued at approximately $3,804,835.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 14,435 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $81.54, for a total transaction of $1,177,029.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 241,102 shares of company stock valued at $18,237,884. 1.30% of the stock is owned by insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.